Media headlines about Organovo (NASDAQ:ONVO) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Organovo earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.9361017650137 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Technical Indicators in Focus – Organovo Holdings Inc (NASDAQ: ONVO) – Alpha Beta Stock (alphabetastock.com)
- Consider EPS Evaluation Before Making Any Investment Decision – Organovo Holdings Inc (NASDAQ: ONVO) – Stocks Market Cap (stocksmarketcap.com)
- Organovo Holdings, Inc. (ONVO) folded -40.94% down SMA-200 – The Stocks News (press release) (thestocksnews.com)
- Technical Indicators under Consideration – Organovo Holdings Inc … – Stocks Market Cap (stocksmarketcap.com)
- Organovo to Present at HC Wainwright Nash Investor Conference – GlobeNewswire (press release) (globenewswire.com)
Separately, Zacks Investment Research downgraded Organovo from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $3.40.
Organovo (NASDAQ:ONVO) last issued its earnings results on Thursday, February 8th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The firm had revenue of $1.15 million for the quarter, compared to analyst estimates of $1.25 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The business’s revenue was up .0% on a year-over-year basis. analysts predict that Organovo will post -0.33 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Organovo (NASDAQ:ONVO) Earns Daily News Sentiment Score of 0.19” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/2018/03/22/organovo-onvo-earns-daily-media-sentiment-rating-of-0-19/1926330.html.
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.